Monte Rosa Therapeutics, Inc. - 10-Q Filing
Monte Rosa Therapeutics reports Q3 2025 financial results featuring collaboration revenue and ongoing R&D investment.
Tickers: $GLUE
Read the full article at SEC EDGAR
Part of the story REGENXBIO Reports Q3 2026 Financial Results Amid Patent Expirations and Litigation Settlement (3 articles)